AddLife AB (ALIF.B) AI Stock Analysis

• Market Cap: $22.32B
• Dividend Yield: 0.36%
• Average Volume (3M): 67.55K
• Price to Earnings (P/E): 65.9
• Beta (1Y): 0.69
• Revenue Growth: 5.14%
• EPS Growth: 236.75%
• Country: SE
• Employees: 2,251
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.29
• Shares Outstanding: 117,877,460
• 10 Day Avg. Volume: 69,103
• 30 Day Avg. Volume: 67,549
• PEG Ratio: 2.03
• Price to Book (P/B): 3.15
• Price to Sales (P/S): 1.63
• P/FCF Ratio: 20.97
• Enterprise Value/Market Cap: 1.24
• Enterprise Value/Revenue: 2.66
• Enterprise Value/Gross Profit: 7.04
• Enterprise Value/Ebitda: 35.70
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 62 Neutral
• Price Target: kr214.00 ▲(4.19% Upside)

AddLife AB's overall stock score is primarily influenced by its solid financial performance, with strong revenue growth and a healthy gross profit margin. However, the high P/E ratio suggests overvaluation, and technical indicators point to an overbought condition, which could lead to a price correction. The company should focus on improving profitability and cash flow stability to enhance its financial standing.

AddLife AB Business Overview & Revenue Model

Company Description

AddLife AB (publ), together with its subsidiaries, provides equipment, medical devices, and reagents primarily to healthcare system, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory equipment for haematology, pathology, point-of-care diagnostics, cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, consumables, and analytical instruments segments. This segment also offers support, maintenance, advice, and training services. The Medtech segment provides medical device products for surgery, respiration, intensive care, wound care, enteral nutrition, fall prevention, welfare technology, ear, and nose and throat segments, as well as bathroom-related assistive devices and assistive devices for children with disabilities. It operates in Sweden, Finland, Denmark, Norway, the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.

How the Company Makes Money

AddLife AB generates revenue through multiple streams, primarily by selling a diverse range of products in the life sciences and medical technology sectors. Key revenue streams include the sale of laboratory equipment, medical devices, and diagnostic products. The company also earns income from services related to the maintenance and support of medical equipment, as well as consultancy services in life sciences. Additionally, AddLife benefits from strategic partnerships with leading manufacturers and suppliers, which enhance its product offerings and market reach. These collaborations enable AddLife to provide cutting-edge solutions to its clients while leveraging shared resources for improved operational efficiency.

AddLife AB Financial Statement Overview

Summary

AddLife AB demonstrates solid financial health with strong revenue and cash flow growth. The company has reduced its financial leverage and maintained profitability, although operational margins have faced slight pressure.

Income Statement

AddLife AB shows strong revenue growth with a significant increase from 2023 to 2024. The gross profit margin is healthy, consistently above 35%. However, the EBIT margin has decreased slightly over the last few years, indicating slight pressure on operational efficiency. The company maintains a solid net profit margin, reflecting overall profitability.

Balance Sheet

The balance sheet is robust with zero total debt in 2024, resulting in a strong equity position. The debt-to-equity ratio has improved significantly, indicating reduced financial leverage and potential risk. The equity ratio remains stable, showcasing a sound financial structure. However, the company should be cautious of any future liabilities that may arise.

Cash Flow

Cash flow from operations has shown impressive growth, indicating strong operational cash generation. The free cash flow growth is substantial, highlighting efficient capital expenditure management. The operating cash flow to net income ratio is favorable, suggesting good cash conversion from profits. These factors contribute to a positive cash flow outlook.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.44B	10.29B	9.69B	9.08B	7.99B	5.27B
Gross Profit	3.95B	3.86B	3.60B	3.43B	2.86B	1.82B
EBITDA	778.00M	1.52B	1.55B	1.45B	1.46B	951.00M
Net Income	337.00M	252.00M	190.00M	480.00M	719.00M	517.80M
Balance Sheet
Total Assets	12.75B	13.05B	12.74B	13.06B	10.60B	4.15B
Cash, Cash Equivalents and Short-Term Investments	253.00M	331.00M	272.00M	376.00M	345.30M	216.00M
Total Debt	5.03B	5.07B	5.29B	5.59B	4.10B	805.80M
Total Liabilities	7.48B	7.75B	7.79B	8.09B	6.30B	2.26B
Stockholders Equity	5.27B	5.31B	4.96B	4.97B	4.29B	1.88B
Cash Flow
Free Cash Flow	1.11B	798.00M	465.00M	627.00M	866.30M	857.90M
Operating Cash Flow	1.16B	1.09B	773.00M	909.00M	1.01B	950.10M
Investing Cash Flow	-531.00M	-386.00M	-317.00M	-1.09B	-2.98B	-428.70M
Financing Cash Flow	-583.00M	-682.00M	-554.00M	134.00M	2.07B	-372.50M

AddLife AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 205.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALIF.B, the sentiment is Positive. The current price of 205.4 is above the 20-day moving average (MA) of 185.76, above the 50-day MA of 182.73, and above the 200-day MA of 171.27, indicating a bullish trend. The MACD of 4.75 indicates Negative momentum. The RSI at 73.71 is Negative, neither overbought nor oversold. The STOCH value of 88.43 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ALIF.B.

AddLife AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIMIAN	―	€16.70B	47.26	4.63%	―	17.13%	―
VITR	―	kr20.47B	46.40	3.34%	0.73%	-1.29%	―
ALIF.B	―	$22.32B	65.92	7.24%	0.36%	5.14%	236.75%
BONEX	―	kr15.54B	102.30	19.59%	―	37.41%	67.03%
PAX	―	$1.58B	142.11	2.64%	―	14.28%	-68.33%
EKTA.B	―	kr19.10B	69.73	2.76%	4.80%	-1.54%	-75.84%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

AddLife AB Corporate Events

AddLife AB Reports Strong Growth and Earnings

AddLife AB Class B is a prominent player in the life sciences sector, specializing in providing advanced products and services in the Labtech and Medtech markets across Europe. The company’s recent earnings report highlights a strong quarter with significant organic growth and improved margins, reflecting its strategic focus on efficiency and product portfolio enhancement. Key financial metrics include a 4% increase in net sales to SEK 2,429 million and a notable 17% rise in EBITA to SEK 270 million, driven by a 6% organic growth rate. The company’s profit after tax surged by 228% to SEK 82 million, and earnings per share increased to SEK 0.66. The acquisition of Edge Medical Ltd. is expected to further bolster annual net sales by approximately SEK 90 million. Looking ahead, AddLife’s management remains optimistic about continued growth and profitability improvements, supported by its strong market position and strategic initiatives in high-margin niches.

AddLife AB Reports Strong Q3 2025 Performance and Strategic Acquisition

AddLife AB reported strong financial performance for the third quarter of 2025, with a 4% increase in net sales and a significant 228% rise in profit after tax. The company also completed the acquisition of Edge Medical Ltd., which is expected to boost annual sales by SEK 90m, further strengthening its market position.

The most recent analyst rating on ($SE:ALIF.B) stock is a Hold with a SEK195.00 price target. To see the full list of analyst forecasts on AddLife AB stock, see the SE:ALIF.B Stock Forecast page.